UUDA Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)966.00
Market Cap
€30.48M
Enterprise Value€21.58
Total Cash (Recent Filing)€13.56M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.09
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,963,019,300
10 Day Avg. Volume2,000
30 Day Avg. Volume966
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)2.06
Price to Sales (P/S)0.00
P/FCF Ratio-3.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.07Price Target Upside225.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageThe absence of meaningful debt limits interest obligations and refinancing risk. This gives Syntara greater financial flexibility than in earlier periods of higher leverage, although the benefit is constrained by ongoing losses and negative cash generation.
Substantial Equity CushionA sizable equity base relative to assets provides a stronger solvency cushion and reduces dependence on creditors. It may help absorb operating losses over the medium term, though continued cash burn could gradually erode this protection.
Prior Gross ProfitabilityThe historical gross margin indicates that Syntara's underlying products or commercial activities have previously supported attractive unit economics. If revenue is restored, this record could provide a foundation for operating leverage, despite current lack of sales.
Bears Say
No Recent RevenueThe absence of recent reported revenue leaves the business without demonstrated commercial scale and makes future results dependent on restarting or establishing sales. This materially weakens revenue visibility and limits confidence in sustainable operations.
Persistent Net LossesContinuing and worsening net losses show that the current cost base is not supported by operating income. Unless revenue returns or expenses are structurally reduced, losses may continue consuming equity and restrict the company's ability to fund development.
Ongoing Cash BurnSustained negative operating and free cash flow indicates that operations require external funding or existing liquidity. Although cash flow improved from FY2025, the multi-year deterioration from positive FY2021 cash flow signals a durable funding risk.
Syntara Limited News
UUDA FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest stock price was €0.01 and its highest was €0.03 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is €30.48M.
When is Pharmaxis Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmaxis Ltd’s earnings last quarter?
Currently, no data Available
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Undervalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,963,019,300 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in DE:UUDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Syntara Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.07 (225.60% Upside)
€0.07 (225.60% Upside)
Blogger Sentiment
Bullish
DE:UUDA Sentiment 82%
Sector Average 60%
Sector Average 60%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pharmaxis Ltd
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Australia, the company's research pipeline focuses on blood cancers as well as a range of inflammatory and fibrotic disorders. Its leading investigational compound, amsulostat, is currently in Phase 1c/2 clinical trials for the treatment of myelofibrosis, a bone marrow cancer, and is also being evaluated for myelodysplastic syndrome. Beyond this, Syntara is advancing several other promising drug candidates. These include a suite of topical pan-LOX inhibitors: SNT-9465, which is undergoing Phase 1a/b study for hypertrophic scars, and SNT-6302, designed for keloid scars. Furthermore, SNT-4728 is in development to manage sleep disorders and to potentially slow the progression of neurodegenerative conditions by mitigating neuroinflammation. The company's broader therapeutic ambitions extend to various fibrotic and inflammatory diseases such as kidney fibrosis, MASH (metabolic dysfunction-associated steatohepatitis), pulmonary fibrosis, and cardiac fibrosis. Incorporated in 1998, the company was formerly known as Pharmaxis Ltd before adopting the name Syntara Limited in December 2023.
UUDA Stock 12 Month Forecast
Average Price Target
€0.07
▲(225.60% Upside)
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―